Enhanced Nanomedicinal Composition for Breast Cancer Treatment

An advanced nanomedicinal composition with improved targeting, delivery, and efficacy for breast cancer treatment, overcoming limitations of existing compositions.

The original patent disclosed a nanomedicinal composition for breast cancer treatment, but it had limitations in terms of targeting, immunogenicity, and sustained release. The new inventive concept addresses these limitations by introducing functionalized porous silicate matrices, hierarchical structures, biocompatible coatings, and sustained release mechanisms.

The new inventive concept comprises a nanomedicinal composition with a porous silicate matrix functionalized with a targeting moiety, ensuring enhanced delivery to cancer cells. The matrix has a hierarchical structure, increasing its surface area for improved loading capacity. The composition is loaded with a pharmaceutical agent mixture and particles of a magnetic ferrite, and coated with a biocompatible polymer to reduce immunogenicity. The composition is designed to release the pharmaceutical agent mixture in a sustained manner over a period of at least 24 hours. Additionally, the composition can be labeled with a fluorescent marker for real-time tracking of its biodistribution.

The new claims introduce novel features such as functionalized porous silicate matrices, hierarchical structures, biocompatible coatings, and sustained release mechanisms, which are not present in the original patent. These features provide an inventive step by addressing the limitations of the original composition and improving its efficacy and safety.

Alternative embodiments of the inventive concept could include different types of targeting moieties, varying hierarchical structures, and diverse biocompatible coatings. Additionally, the composition could be adapted for treating other types of cancer or diseases.

The enhanced nanomedicinal composition has significant commercial potential in the breast cancer treatment market, with potential applications in other cancer types and diseases. The market for nanomedicinal compositions is growing, driven by the need for more effective and targeted treatments.